IGMPI facebook Biodexa reports an R&D update including positive results from the phase I trial of MTX110 in patients with diffuse midline glioma
IGMPI Logo
इंस्टीट्यूट ऑफ गुड मैन्यूफैक्चरिंग प्रैक्टिसेज इंडिया
Institute of Good Manufacturing Practices India

(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)

18001031071 (Toll Free), +91 11 26512850
Regular Classroom | Online Mode

Biodexa reports an R&D update including positive results from the phase I trial of MTX110 in patients with diffuse midline glioma

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, shares an R&D update. Positive top-line results from a recent phase 1 trial of MTX110 in diffuse midline glioma (DMG) patients and preclinical data on tolimidone's beta cell proliferation potential are highlighted.

In a Columbia University Irving Medical Center study, DMG patients received MTX110 via convection-enhanced delivery (CED). Safety was paramount, with infusions limited to two sessions. Despite the trial's primary focus on safety, patients showed a median overall survival of 16.5 months, surpassing historical rates.

Detailed trial results will be presented at the 21st International Symposium on Paediatric Neuro-Oncology (ISPNO 2024). Meanwhile, an inconclusive in vitro experiment assessing tolimidone's beta cell proliferation potential prompts further in vivo preclinical studies. Plans for a phase IIa trial in type 1 diabetes patients are underway.

Biodexa Pharmaceuticals PLC is dedicated to developing innovative treatments for diseases with unmet medical needs.